appli
engin
principl
biolog
synthet
biolog
becom
scienc
reassembl
catalogu
standard
biolog
compon
systemat
ration
manner
creat
engin
function
biolog
design
devic
system
organ
predict
use
novel
function
synthet
biolog
abl
use
inventori
biomolecular
part
compil
year
molecular
biolog
function
genom
well
technolog
made
possibl
genet
compon
live
organ
although
recent
becom
possibl
reconstruct
live
organ
transfer
synthet
genom
assembl
chemic
synthes
nucleic
acid
ration
design
stateoftheart
biolog
circuit
predic
function
remain
challeng
appar
limit
hand
synthet
circuitri
compos
basic
heterolog
control
compon
finetun
transgen
express
respons
specif
exogen
cue
endogen
gene
switch
includ
triggerinduc
control
transcript
translat
respons
heterolog
endogen
input
signal
fig
standard
design
gene
switch
improv
function
enabl
construct
higherord
network
includ
multitrigg
input
sequenti
mutual
feedback
circuit
compon
abl
provid
complex
protein
express
dynam
high
precis
predict
logic
respons
extern
cue
physiolog
pathway
control
compon
function
differ
bacteri
eukaryot
speci
minor
gene
switch
network
blueprint
pioneer
bacteria
yeast
often
fulli
function
mammalian
cell
exampl
synthet
network
similar
compon
circuit
topolog
bacteri
mammalian
cell
includ
regulatori
epigenet
toggl
hysteret
molecular
time
synthet
ecosens
system
synthet
quorumsens
system
synthet
hormon
bandpass
differ
type
oscil
program
rhythmic
transgen
express
tunabl
frequenc
firstgener
synthet
circuit
oper
isol
without
interfac
metabol
host
cell
use
program
specif
cellular
function
use
heterolog
extern
input
key
challeng
often
occur
biomed
set
need
specif
precis
drugdos
regim
minim
side
effect
shorten
diagnosistotreat
timelin
avoid
drugresist
pathogen
synthet
biolog
enabl
engin
complex
highprecis
control
devic
coupl
sens
deliveri
mechan
emerg
scienc
may
abl
offer
tool
suit
meet
current
biomed
challeng
new
way
decad
pioneer
synthet
network
first
success
therapeut
applic
anim
model
promin
human
diseas
start
review
focus
recent
progress
synthet
biolog
toward
improv
human
health
includ
diagnost
applic
design
novel
prevent
care
strategi
progress
drug
discoveri
design
deliveri
develop
novel
treatment
strategi
prosthet
network
synthet
biolog
hold
promis
provid
uniqu
opportun
major
advanc
improv
human
health
twentyfirst
understand
diseas
mechan
pathogen
mechan
avail
afford
technolog
synthes
sequenc
protein
genom
increas
speed
dramat
improv
understand
interact
diseas
mechan
synthet
biolog
principl
analysi
synthesi
provid
mechanist
insight
combin
rapid
synthesi
assembl
shuffl
mutat
individu
genet
compon
straightforward
function
analysi
exampl
genom
viru
respons
spanish
influenza
pandem
synthes
use
sequenc
inform
genom
piec
extract
permafrostconserv
tissu
sampl
function
analysi
reconstruct
viru
provid
new
insight
key
virul
factor
pathogen
name
haemagglutinin
variant
induc
membran
fusion
without
trypsin
activ
modifi
polymeras
enhanc
viral
studi
also
reveal
combin
eight
gene
respons
except
virul
spanish
influenza
find
may
help
identifi
pandem
potenti
futur
viru
synthesi
analysi
chimer
virus
also
made
substanti
contribut
understand
coronaviru
zoonos
respons
sever
acut
respiratori
syndrom
sar
pandem
character
histori
sar
coronaviru
especi
switch
tropism
particularli
challeng
direct
ancestor
could
propag
laboratori
model
howev
kb
sarslik
bat
coronaviru
design
contain
receptorbind
spike
protein
human
homologu
synthes
chimer
viru
abl
replic
cultur
infect
vivo
studi
reveal
infectionenhanc
mutat
spike
protein
establish
surfac
protein
key
factor
respons
tropism
switch
coronaviru
reconstruct
pathogen
dna
synthesi
also
use
product
diagnost
highdens
antigen
use
profil
postlymediseas
humour
immun
respons
hepat
c
human
immunodefici
viru
hiv
immun
system
synthet
biolog
recent
provid
new
insight
disord
relat
defici
immun
system
known
particularli
complex
control
circuit
cellular
interact
network
exampl
dysfunct
blymphocyt
activ
underli
sever
physiolog
function
reconstitut
analysi
human
b
cell
antigen
receptor
bcr
signal
cascad
insect
cell
reveal
bcr
activ
antigenspecif
crosslink
present
textbook
instead
autoinhibitori
oligomer
conform
rest
b
lymphocyt
shift
activ
dissoci
form
antigen
trigger
signal
cascad
result
antibodi
product
onset
humour
immun
respons
also
construct
represent
complet
human
peptidom
engin
display
surfac
phage
enabl
church
discov
new
autoantigen
use
patientderiv
autoantibodi
enrich
autoantigen
peptid
display
phage
could
identifi
antigen
highthroughput
sequenc
knowledg
antigen
involv
autoimmun
process
import
understand
diseas
aetiolog
develop
accur
diagnost
test
design
drug
neutral
autoreact
immun
diseas
prevent
vaccin
highthroughput
highprecis
assembl
engin
entir
genom
welldefin
genet
compon
use
synthet
biolog
principl
provid
new
opportun
design
attenu
pathogen
use
vaccin
exampl
primat
immun
viruslik
particl
produc
select
express
particular
chikungunya
viru
chikv
structur
protein
protect
viraemia
highdos
challeng
even
immunodefici
mice
treat
monkeyderiv
antibodi
surviv
subsequ
lethal
dose
dna
synthesi
assembl
also
play
essenti
part
pioneer
safe
live
vaccin
polioviru
attenu
systemat
genomescal
chang
adjac
pair
codon
underrepres
codon
set
viral
capsid
gene
exampl
gccgaa
strongli
underrepres
compar
gcagag
although
encod
chang
reduc
translat
impair
replic
compet
infect
viru
attenu
polioviru
provid
protect
immun
mice
offer
high
safeti
standard
given
low
probabl
individu
chang
revert
thu
reconstitut
infecti
wildtyp
virus
genomeengin
approach
use
could
repres
gener
strategi
design
live
vaccin
infecti
diseas
promis
vaccin
concept
includ
use
antigenproduc
immunostimulatori
liposom
genet
programm
synthet
product
heatstabl
oral
algaebas
vaccin
protect
staphylococcu
aureu
vector
control
suppress
insect
vector
popul
use
transgen
viral
strain
harbour
condit
dominantleth
synthet
circuitri
may
control
transmiss
malaria
parasit
dengu
virus
could
eventu
control
spread
untreat
mosquito
transgen
tetracyclinedepend
transactiv
tta
exclus
express
femal
indirect
flight
muscl
propag
presenc
tetracyclin
repress
transcript
gene
howev
absenc
tetracyclin
lead
develop
femalespecif
flightless
put
egg
transgen
mosquito
ecosystem
result
maleonli
releas
femal
mosquito
remain
ground
feed
mate
take
blood
meal
effect
repres
lethal
phenotyp
male
transmit
diseas
dissemin
synthet
circuit
across
resid
wildtyp
mosquito
fig
similarli
synthet
home
endonucleasebas
gene
drive
system
could
use
spread
genet
modif
malaria
resist
engin
mosquito
field
popul
home
endonucleas
typic
produc
singl
sequencespecif
doublestrand
break
host
genom
repair
homolog
recombin
use
home
endonucleas
gene
heg
templat
consequ
selfish
heg
copi
broken
chromosom
gene
convers
process
refer
home
express
heg
iscei
control
male
germlin
promot
enabl
effici
home
transheterozyg
male
rapid
genet
drive
led
heg
invas
cage
mosquito
fig
engin
sequenc
specif
heg
exampl
ianii
icrei
gene
drive
concept
could
principl
use
knock
knock
gene
function
target
mosquito
abil
serv
diseas
field
test
releas
insect
carri
domin
lethal
ridl
technolog
use
firstgener
ttatransgen
mosquito
alreadi
conduct
grand
cayman
first
smallscal
releas
confirm
transgen
male
could
surviv
mate
wild
femal
produc
transgen
larva
full
field
trial
show
reduct
number
wild
mosquito
week
releas
studi
site
isol
surround
area
contain
high
densiti
wildtyp
mosquito
score
actual
suppress
effici
remain
drug
develop
drug
discoveri
synthet
mammalian
transcript
circuit
consist
chimer
smallmoleculerespons
transcript
factor
cognat
synthet
promot
origin
design
futur
genebas
therapi
aim
adjust
therapeut
transgen
express
mammalian
cell
respons
pharmacolog
activ
chimer
transcript
factor
deriv
repressor
manag
drug
resist
bacteria
exampl
resist
promiscu
structur
relat
compound
mammalian
cell
contain
circuitri
could
also
use
revers
mode
integr
screen
devic
classspecif
discoveri
new
drug
exampl
new
fig
mammalian
cell
transgen
screen
circuit
expos
compound
librari
detect
modul
report
gene
express
presenc
nontox
cellperm
bioavail
molecul
classspecif
core
structur
correspond
drug
activ
exampl
antibiot
activ
fig
use
screen
setup
compound
detect
lock
transcript
factor
onto
dna
may
block
induct
antibiot
resist
pathogen
render
exampl
see
bioversi
use
compound
alongsid
specif
antibiot
may
offer
novel
antiinfect
treatment
opportun
new
life
cycl
establish
antibiot
fig
triggerinduc
transcript
control
system
use
manner
well
respons
tetracyclin
macrolid
antidiabet
immunosuppress
one
exampl
efficaci
transcript
circuit
system
involv
bacteri
transcript
repressor
ethr
ethr
repress
transcript
etha
prevent
ethamedi
convers
lastlinedef
antibiot
ethionamid
pathogenkil
chemic
best
known
strawberri
flavour
first
compound
found
specif
inactiv
ethr
trigger
etha
express
reestablish
sensit
mycobacterium
tuberculosi
ethionamid
fig
work
reveal
ethrinactiv
ethionamid
booster
compound
also
success
test
mous
model
human
restor
drug
sensit
pharmacolog
inhibit
master
resist
regul
may
wide
exampl
use
synthet
circuitri
drug
discoveri
provid
mammalian
cell
condit
arrest
phase
cell
cycl
circuitri
control
express
cyclinedepend
kinas
inhibitor
cell
reproduc
form
mixtur
isogen
subpopul
proliferationinhibit
cell
prolifer
cell
spontan
escap
synthet
cell
cycl
cell
could
use
cellbas
cancer
model
could
use
screen
anticanc
compound
select
elimin
prolifer
cell
leav
arrest
one
drug
product
drug
deliveri
synthet
pathway
creat
assembl
enzymat
cascad
network
bacteria
yeast
plant
instrument
largescal
econom
product
highvalu
drug
drug
precursor
compound
well
biosynthesi
new
secondari
metabolit
novel
therapeut
activ
exampl
includ
complex
halogen
precursor
antimalaria
drug
artemisinin
produc
compani
amyri
exampl
anticanc
compound
product
compound
necessari
overcom
sever
challeng
includ
function
express
complex
biosynthet
enzym
cytochrom
overal
orchestr
multistep
pathway
avoid
accumul
toxic
intermedi
product
ensur
metabol
smallmoleculerespons
interact
use
pioneer
gene
switch
mammalian
also
success
reengin
design
triggerinduc
biohybrid
materi
drug
use
synthet
monom
hydrogel
produc
dissolv
specif
ligand
suppli
fig
biopharmaceut
exampl
vascular
endotheli
growth
factor
vegf
suppli
gel
format
load
hydrogel
releas
dosedepend
manner
subcutan
implant
mice
oral
administr
trigger
thought
triggerinduc
interact
could
use
produc
drugsens
drugreleas
novel
treatment
infect
break
bacteri
resist
design
phage
biofilm
surfaceassoci
bacteri
commun
encas
hydrat
extracellular
polymer
substanc
ep
matrix
compos
polysaccharid
protein
nucleic
acid
lipid
crucial
pathogenesi
mani
clinic
import
bacteria
exhibit
resist
immun
system
antimicrobi
treatment
make
difficult
collin
success
engin
bacteriophag
constitut
express
dspb
enzym
hydrolys
adhesin
requir
biofilm
format
integr
staphylococcu
spp
escherichia
coli
clinic
isol
initi
infect
bacteri
biofilm
bacteriophag
known
result
rapid
multipl
phage
express
dspb
follow
lysi
dspb
releas
biofilm
lead
reinfect
degrad
process
infect
bacteri
biofilm
cell
count
reduc
two
order
magnitud
greater
nonenzymat
phage
followup
studi
bacteriophag
engin
express
suppress
so
dna
repair
system
bacteria
requir
counteract
antibioticinduc
oxid
infect
design
phage
sensit
e
coli
quinolon
antibiot
use
phage
increas
surviv
mice
infect
e
coli
decreas
surviv
antibioticresist
bacteria
persist
cell
biofilm
cell
reduc
number
antibioticresist
bacteria
aris
antibiotictr
popul
also
act
strong
adjuv
bactericid
design
phage
platform
use
produc
antibiot
although
abandon
introduct
antibiot
phage
therapi
current
revisit
sever
clinic
trial
around
world
preval
multidrugresist
pathogen
dramat
increas
although
phage
therapi
may
face
clinic
challeng
associ
develop
bacteri
phage
resist
phage
neutral
immun
system
pharmacokinet
field
certainli
receiv
impetu
design
engin
probiot
bacteria
decreas
pathogen
virul
bacteria
commun
use
chemic
languag
known
quorum
sens
individu
bacteria
produc
secret
signal
molecul
call
autoinduc
common
multipl
speci
speciesspecif
molecul
accumul
popul
grow
bind
receptor
coordin
colonywid
gene
express
manipul
behaviour
bacteri
popul
exampl
vibrio
cholera
produc
cholera
autoinduc
autoinduc
trigger
repress
key
virul
factor
feed
infant
mice
probiot
e
coli
natur
produc
engin
constitut
synthes
significantli
increas
anim
surviv
rate
ingest
v
suggest
approach
could
econom
strategi
prevent
infecti
diseas
unlik
antibiot
quorumsensingbas
intervent
kill
pathogen
reprogram
behaviour
strategi
may
free
select
pressur
therefor
may
less
prone
develop
resist
anoth
studi
commens
bacteria
equip
synthet
circuitri
stimul
glucosedepend
insulin
product
intestin
epitheli
cancer
therapi
despit
decad
progress
cancer
therapi
major
challeng
remain
specif
target
select
kill
neoplast
cell
develop
within
nativ
implant
tissu
reloc
within
organ
form
metastasi
therefor
therapeut
strategi
design
elimin
cancer
cell
must
extrem
precis
exclus
target
diseas
tissu
leav
normal
tissu
intact
although
nativ
cytotox
constitut
express
anticanc
compound
demonstr
potenti
anim
studi
human
clinic
triggerinduc
drug
express
circuit
deliv
tumourinvas
bacteria
tumourtransduc
viral
particl
may
improv
cancer
therapi
synthet
biologist
recent
design
anticanc
devic
provid
precis
time
locat
dose
drug
product
extern
cue
could
provid
greater
intratumour
effect
minim
system
toxic
bacteri
synthet
devic
intraven
inject
oral
administr
mani
bacteri
speci
exampl
e
coli
salmonella
spp
natur
sens
selfpropel
toward
tumour
bacteria
also
engin
select
invad
prolifer
tumour
tissu
produc
cytotox
compound
well
report
protein
noninvas
followup
monitor
tumour
bacteria
express
flagella
penetr
tissu
chemotact
receptor
promot
migrat
toward
aspart
produc
viabl
cancer
cell
ribos
releas
necrot
tissu
hypox
region
gener
hypermetabol
activ
neoplast
cell
reach
tumour
site
bacteria
either
prolifer
extracellular
space
invad
tumour
cell
either
situat
select
cytotox
engin
express
toxin
cytokin
tumour
antigen
proapoptot
factor
prodrugconvert
noninvas
e
coli
success
program
invad
cultur
tumour
cell
hypoxiarespons
populationdensitydepend
manner
correspond
circuitri
consist
anaerob
induc
format
dehydrogenas
promot
drive
yersinia
pseudotuberculosi
invasin
gene
inv
mediat
invas
use
specif
integrin
receptor
typic
express
tumour
cell
populationdensitydepend
invas
requir
engin
quorumsens
circuit
trigger
inv
express
bacteri
popul
reach
threshold
size
tumour
site
circuitri
consist
quorumsens
receptor
luxr
coinduc
luxi
encod
enzym
produc
quorumsens
messeng
autoinduc
inv
luxrmedi
express
luxi
repres
posit
feedback
loop
amplifi
inv
express
product
coordin
broadcast
invas
order
across
entir
fig
tumourinvad
bacteria
also
engin
triggerinduc
drug
express
enter
tumour
cell
addit
drug
express
synthet
salicylatetrigg
express
devic
use
control
express
drug
compon
follow
system
administr
trigger
molecul
mice
tumour
cell
invad
salmonella
devic
base
circuit
deriv
pseudomona
putida
control
express
cytosin
deaminas
salicylateinduc
mammalian
cell
normal
lack
cytosin
deaminas
mean
resist
enzym
need
convert
cytotox
molecul
tumourbear
mice
inject
attenu
salmonella
enterica
engin
p
putidaderiv
circuit
treat
mice
show
signific
tumour
regress
fed
acetylsalicyl
acid
aspirin
rapidli
convert
salicyl
intak
anim
fig
rnai
potent
highli
conserv
mechan
target
knockdown
mrna
translat
small
rna
nonpathogen
e
coli
engin
express
short
rna
hairpin
trigger
rnai
catenin
coloncancerspecif
bacteria
also
engin
express
protein
mediat
cellular
invas
escap
phagosom
administ
oral
intraven
significantli
reduc
catenin
level
intestin
epithelium
human
colon
cancer
xenograft
fig
combin
variou
bacteri
anticanc
treatment
strategi
may
increas
safeti
specif
effici
futur
clinic
trial
viral
synthet
devic
virus
also
success
engin
transduc
specif
cell
express
epitop
recogn
particular
cellsurfac
receptor
express
prodrug
convertas
cytokin
use
cancer
oncolyt
virus
carri
code
viral
nucleic
acid
may
caus
side
effect
owe
recombin
host
chromosom
provir
element
alreadi
host
cell
recent
synthet
viral
particl
design
lack
code
nucleic
acid
exclus
packag
therapeut
protein
releas
dosedepend
exampl
viral
particl
carri
linamaras
manihot
esculenta
inject
human
breast
cancer
xenograft
mice
treat
nontox
natur
product
linamarin
virus
trigger
effici
tumour
regress
owe
cyanid
produc
linamarasemedi
convers
fig
similarli
proteincarri
viral
nanoparticl
use
deliv
sitespecif
dna
recombinas
flp
precis
integr
excis
genet
compon
host
might
also
use
deliv
nativ
chimer
transcript
factor
could
transient
control
express
target
gene
involv
therapeut
intervent
lineag
control
induct
transform
sensor
cancer
therapi
gene
therapi
advanc
cancer
includ
virusmedi
deliveri
cytotox
effector
gene
control
cancerspecif
deliveri
chimer
adaptor
protein
link
tyrosin
kinas
signal
apoptosisinduc
caspas
promot
control
circuit
coordin
simpl
reaction
inher
noisi
allow
linear
respons
mean
limit
control
specif
efficaci
howev
use
two
intern
input
signal
improv
fidel
mediat
sharp
respons
profil
ensur
robust
biochem
use
decisionmak
circuit
blueprint
nissim
design
tunabl
dual
promot
integr
dpi
target
cancer
cell
precis
dpi
consist
two
nativ
promot
concurr
activ
two
independ
transcript
factor
cancersens
promot
produc
differ
fusion
protein
proport
activ
two
protein
assembl
togeth
chimer
transcript
factor
transcript
factor
activ
synthet
promot
control
express
herp
simplex
viru
type
thymidin
kinas
cytotox
presenc
nucleotid
analogu
ganciclovir
fig
dpi
could
optim
specif
cancer
cell
type
use
differ
combin
input
promot
effector
gene
well
modul
assembl
effici
half
life
chimer
transactiv
compon
far
set
three
promot
character
detail
dpi
design
may
accommod
suitabl
promot
recent
develop
celltyp
classifi
conceptu
similar
dpi
also
program
destroy
cell
express
specif
set
neoplast
celltyp
classifi
combin
transcript
translat
control
compon
singl
scalabl
synthet
circuit
sens
express
level
set
current
six
endogen
microrna
mirna
trigger
apoptosisinduc
respons
level
match
preset
profil
celltyp
classifi
combin
sensor
modul
detect
highli
lowli
express
mirna
fig
clinic
implement
dpi
celltyp
classifi
must
either
deliv
cancer
tissu
must
provid
failsaf
mechan
constantli
elimin
transform
cell
engin
tissu
implant
emerg
tool
biomedicin
novel
treatment
strategi
requir
new
technolog
sens
control
diseas
synthet
biologist
design
new
devic
could
sens
key
physiolog
activ
found
new
way
dose
therapeut
intervent
precis
respons
extern
physic
cue
synthet
devic
could
widerang
biomed
applic
rna
control
cell
prolifer
thu
far
synthet
control
devic
design
interfac
host
metabol
reprogram
cellular
behaviour
larg
limit
heterolog
transcript
factor
rna
control
may
repres
altern
straightforward
design
integr
singl
express
unit
contain
sensor
aptam
generegulatori
compon
ribozym
effector
inher
modular
compat
rnabas
control
compon
enabl
independ
optim
exchang
exampl
rna
control
devic
consist
drugrespons
aptam
link
ribozym
untransl
region
utr
cytokin
express
unit
enabl
triggerinduc
inactiv
ribozymemedi
transcript
cleavag
full
transgen
express
presenc
input
synthet
rna
control
devic
appli
control
prolifer
engin
primari
human
cell
enabl
extern
control
expans
transgen
cell
implant
mice
synthet
rna
control
devic
could
provid
advanc
necessari
enabl
cell
contrast
stateoftheart
triggerinduc
expans
engin
cell
use
chimer
antigen
receptor
led
moder
prolifer
poor
surviv
cell
clinic
anoth
use
synthet
rna
design
programm
devic
convert
level
intracellular
protein
discret
high
low
transgeneexpress
rna
devic
consist
threeexon
twointron
minigen
follow
transgen
intron
contain
proteinsens
aptam
central
exon
includ
stop
codon
bind
protein
aptam
control
splice
minigen
central
exon
splice
transgen
express
high
level
remain
unsplic
transgen
express
low
level
devic
configur
sens
subunit
nuclear
factor
kappa
b
neoplast
marker
express
herp
simplex
viru
thymidin
kinas
thymidin
kinas
render
cell
suscept
ganciclovir
devic
oper
cancer
kill
switch
presenc
cancer
marker
modular
configur
rna
devic
allow
tailor
differ
intracellular
protein
even
multiprotein
input
use
specif
intron
aptam
also
respons
perform
tune
place
aptam
differ
locat
within
intron
avail
compact
rna
easi
design
alter
control
transgen
express
respons
intracellular
level
key
protein
may
also
improv
abil
link
metabol
diseas
state
genebas
therapeut
intervent
optogenet
devic
blood
glucos
homeostasi
light
becom
increasingli
popular
traceless
moleculefre
input
signal
trigger
transgen
express
live
system
bacteria
engin
record
project
imag
gigapixel
adjust
transgen
express
respons
multichromat
genet
light
switch
also
design
control
gene
shape
mammalian
devic
convert
light
puls
transcript
may
foster
novel
therapeut
opportun
futur
gene
cellbas
therapi
may
improv
manufactur
difficulttoproduc
protein
pharmaceut
cancer
therapeut
illustr
exampl
lightcontrol
express
glucagonlik
peptid
promis
drug
candid
treatment
type
fig
optogenet
devic
enabl
lighttrigg
gene
express
human
cell
design
involv
ectop
express
melanopsin
human
embryon
kidney
cell
function
rewir
signal
downstream
melanopsin
cascad
integr
bluelightpulsetrigg
photorecept
produc
revers
sustain
intensitydepend
transcript
respons
place
hollow
fibr
contain
implant
mice
transgen
express
engin
lightsensit
cell
could
control
remot
optic
illumin
mice
carri
subcutan
implant
microencapsul
photorespons
cell
also
enabl
transderm
control
transgen
express
correspond
protein
level
blood
treat
anim
system
abl
attenu
glycaem
excurs
control
glucos
homeostasi
mous
model
human
type
prosthet
network
prosthet
network
synthet
devic
act
molecular
prosthes
engin
cell
function
connect
host
metabol
sens
monitor
score
diseaserelev
metabolit
process
offlevel
concentr
coordin
adjust
diagnost
prevent
therapeut
respons
seamless
automat
selfsuffici
manner
exampl
use
prosthet
network
sens
metabolit
improv
control
urat
homeostasi
fig
moder
level
uric
acid
scaveng
radic
deem
benefici
howev
transient
surg
uric
acid
releas
die
cell
cancer
therapi
lead
tumour
lysi
syndrom
chronic
hyperuricaemia
result
gout
human
particularli
sensit
imbal
urat
homeostasi
lack
uricolyt
activ
prosthet
network
constantli
monitor
blood
urat
concentr
restor
urat
homeostasi
control
express
urat
oxidas
reduc
excess
urat
concentr
preserv
level
suitabl
radic
scaveng
could
repres
treatment
strategi
hyperuricaem
brief
human
cell
contain
prosthet
network
recent
design
combin
uric
acid
sensor
manag
oxid
stress
protect
deinococcu
radioduran
human
uric
acid
transport
also
known
increas
intracellular
uric
acid
level
thu
sensit
prosthet
circuit
secretionengin
urat
oxidas
smuox
clinic
licens
treatment
tumour
lysi
prosthet
uricacidrespons
express
network
urex
abl
sens
uric
acid
concentr
precis
activ
secret
smuox
uric
acid
concentr
patholog
level
secret
smuox
stop
soon
uric
acid
concentr
return
homeostasi
level
impress
demonstr
urextransgen
cell
implant
urateoxidasedefici
mice
develop
acut
hyperuricaemia
symptom
similar
human
gout
urex
abl
degrad
urat
restor
urat
homeostasi
blood
result
dissolut
uric
acid
crystal
deposit
kidney
treat
straightforward
design
may
allow
urex
serv
blueprint
assembl
prosthet
network
sens
metabol
disturb
circul
patholog
metabolit
artifici
insemin
devic
artifici
insemin
standard
practic
facilit
human
reproduct
livestock
breed
broad
variat
oestru
express
ovul
time
coordin
sperm
deliveri
femal
oestru
still
major
challeng
ovul
trigger
specif
time
pituitari
gland
releas
lutein
hormon
bind
lutein
hormon
receptor
lhr
coordin
releas
oocyt
integr
synthet
signal
cascad
advanc
biomateri
kemmer
design
artifici
insemin
devic
coordin
sperm
deliveri
oestru
control
artifici
insemin
devic
consist
cellulos
sulphat
capsul
contain
bull
sperm
sensor
sensor
cell
engin
express
lhr
constitut
activ
trigger
express
cellulas
secret
implant
cow
uteru
sensor
cell
line
constantli
monitor
anim
lutein
hormon
level
oestrustrigg
surg
lutein
hormon
level
lead
product
secret
cellulas
degrad
implant
capsul
result
time
deliveri
sperm
success
concept
fine
tune
design
cascad
could
enabl
use
speci
includ
human
perspect
conclus
recent
year
synthet
biolog
substanti
advanc
strategi
classic
biomed
applic
pathogen
diseas
screen
drug
progress
may
immin
develop
shorter
drug
drug
develop
timelin
increas
precis
drug
product
new
afford
ultim
sophist
therapeut
devic
sens
disturb
seek
patholog
condit
restor
function
roadmap
therapeut
network
connect
diagnost
input
therapeut
output
may
provid
allinon
diagnost
prevent
therapeut
solut
futur
gene
cellbas
therapi
match
diagnost
outcom
highend
therapi
recent
becom
focu
pharmaceut
industri
declar
person
medicin
treatment
strategi
futur
tool
tremend
impact
futur
biomed
applic
includ
use
lightactiv
trigger
bring
precis
therapeut
respons
program
bacteria
seek
destroy
cancer
use
synthet
circuitri
keep
crucial
metabolit
homeostat
manag
diseasecontrol
elimin
specif
cell
recent
work
shown
principl
possibl
devic
work
expect
produc
therapeut
impact
anim
model
human
implant
consist
engin
microencapsul
cell
repres
way
introduc
prosthet
network
predefin
function
instead
directli
target
host
cell
genet
materi
although
implant
contain
cell
engin
prosthet
network
certainli
promis
way
forward
limit
biomed
applic
extracellular
diseas
metabolit
therapeut
address
vascular
system
howev
still
long
way
go
syntheticbiologybas
biomed
devic
clinic
realiti
place
therapeut
circuit
specif
cell
patient
make
sure
interfer
human
metabol
import
challeng
therefor
clinic
use
syntheticbiologybas
devic
therapeut
scenario
face
scientif
ethic
legal
issu
gene
cellbas
therapi
may
offer
complex
control
dynam
therefor
expect
higher
therapeut
impact
although
none
synthet
devic
prosthet
network
relat
product
pioneer
synthet
biologist
yet
use
clinic
clinic
trial
stage
set
novel
treatment
strategi
avail
commit
pharmaceut
industri
place
synthet
biolog
deliv
biomedicin
twentyfirst
centuri
